CKD-MBD stands for Chronic Kidney Disease-Mineral and Bone Disorder, a syndrome that develops when failing kidneys can no longer keep minerals like calcium and phosphorus in balance. It’s not just a bone problem. The condition is defined by three interconnected components: abnormal blood levels of calcium, phosphorus, and parathyroid hormone; weakened and structurally altered bones; and calcification of blood vessels and soft tissues. Roughly 40% to 50% of people with stage 3 CKD already show these mineral abnormalities, and that figure climbs to 80% to 90% by stage 5.
How Healthy Kidneys Keep Minerals in Check
In a healthy body, your kidneys act as the central control system for calcium and phosphorus. When you eat foods containing phosphorus, a hormone called FGF23 is released from bone cells. FGF23 signals the kidneys to flush out excess phosphorus in urine and dials down the production of active vitamin D, which in turn limits how much phosphorus and calcium your gut absorbs from food. Parathyroid hormone, produced by four small glands in your neck, works alongside FGF23 to fine-tune calcium levels, pulling calcium from bones when blood levels dip too low.
This system depends on kidneys that can respond to those hormonal signals. When kidney function declines, the whole feedback loop starts to unravel.
What Goes Wrong as Kidneys Decline
The disruption begins earlier than most people expect. Even in early CKD, the kidneys struggle to excrete phosphorus efficiently. FGF23 levels rise as a compensatory response, sometimes before any change shows up on a standard blood test. This surge in FGF23 suppresses active vitamin D production, which means your gut absorbs less calcium. Lower calcium then triggers the parathyroid glands to ramp up parathyroid hormone secretion.
For a while, this compensation works. FGF23 forces the remaining functional kidney tissue to excrete more phosphorus per unit, and blood phosphorus may actually stay normal or even dip slightly. But as kidney function continues to fall, the system can no longer keep up. Phosphorus accumulates in the blood (hyperphosphatemia), parathyroid hormone stays chronically elevated, active vitamin D drops further, and calcium levels become unstable. This cascade is the biochemical pillar of CKD-MBD.
The Bone Component: Renal Osteodystrophy
The bone disease that develops within CKD-MBD is called renal osteodystrophy, and it comes in two broad forms classified by how quickly bone is being remodeled.
High-turnover bone disease happens when chronically elevated parathyroid hormone drives excessive bone breakdown. Bone is resorbed faster than it’s rebuilt, leading to progressive bone loss. The classic form of this, historically called osteitis fibrosa cystica, leaves bones porous and fragile.
Low-turnover bone disease, sometimes called adynamic bone disease, is in some ways the opposite problem. Both bone formation and bone resorption slow dramatically, but resorption still outpaces formation. The result is the same: reduced bone volume and increased fracture risk. This form can develop when parathyroid hormone is over-suppressed by treatment or when other factors impair normal bone cell activity.
The fracture consequences are severe. Dialysis patients have a hip fracture rate four times higher than the general population after adjusting for age, sex, and ethnicity. After four years on dialysis, the risk is roughly 8 to 10 times that of the general population. And when people with reduced kidney function do fracture a hip, their mortality risk is about twice as high as it is for people with normal kidney function.
Vascular Calcification and Heart Risk
The third component of CKD-MBD, and arguably the most dangerous, is the calcification of blood vessels. When phosphorus levels stay elevated, the excess mineral doesn’t just sit passively in the bloodstream. High phosphorus triggers cells lining blood vessel walls to behave more like bone-forming cells, actively depositing calcium and phosphorus into the vessel walls. This process is driven by the elevated calcium-phosphorus product in the blood.
At the same time, excessive bone resorption releases stored calcium and phosphorus back into circulation, further fueling vascular calcification. This creates a vicious cycle: weakening bones feed minerals into the blood, and those minerals stiffen arteries. Calcified arteries become rigid, raising blood pressure and forcing the heart to work harder. Over time, this promotes thickening of the heart’s left ventricle, a major risk factor for heart failure and sudden cardiac death.
Three factors within CKD-MBD have been identified as independent cardiovascular risk factors: high phosphorus levels, vascular calcification itself, and elevated FGF23. This is a major reason why cardiovascular disease is the leading cause of death in people with CKD, not kidney failure itself.
How CKD-MBD Is Detected
Diagnosis relies primarily on blood tests. The key markers are serum phosphorus, calcium, parathyroid hormone, active vitamin D, and in some cases FGF23 (though FGF23 testing isn’t yet routine in clinical practice). These labs are monitored regularly as CKD progresses, with increasing frequency at later stages.
Imaging plays a supporting role. Bone density scans can identify bone loss, and lateral abdominal X-rays can detect vascular calcification. However, the gold standard for classifying the exact type of bone disease is a bone biopsy, which is evaluated based on three characteristics: turnover (how fast bone is being remodeled), mineralization (how well new bone is calcifying), and volume (how much bone tissue remains). In practice, biopsies are reserved for cases where the type of bone disease is unclear and the treatment approach depends on knowing it.
Managing Phosphorus Through Diet
Dietary phosphorus restriction is the foundation of CKD-MBD management. Guidelines recommend limiting phosphorus intake to 800 to 1,000 mg per day. Since protein-rich foods are the main source of dietary phosphorus, this requires careful food choices rather than simply eating less.
One of the biggest hidden sources of phosphorus is processed food. Nearly all processed foods contain phosphate additives used to preserve color and extend shelf life. These additives (listed on labels as disodium phosphate, monosodium phosphate, potassium triphosphate, and similar names) are absorbed much more efficiently by the gut than the phosphorus naturally present in whole foods. Reading ingredient lists matters more than reading nutrition labels, since phosphorus content isn’t always listed in the nutrition facts.
Shifting toward plant-based protein sources can help. Phosphorus in grains, legumes, and vegetables is bound in a form called phytate that humans absorb poorly, meaning you get the protein without as much of the phosphorus load. A grain-based vegetarian diet can provide adequate protein while keeping phosphorus levels more manageable.
Medications That Target CKD-MBD
When dietary changes alone aren’t enough, three main classes of medication come into play.
- Phosphate binders: These are taken with meals and work by binding to phosphorus in food before it can be absorbed. Some are calcium-based, which also provide supplemental calcium but carry a risk of driving calcium levels too high. Calcium-free options avoid that problem and are often preferred, especially in patients who already have vascular calcification.
- Active vitamin D therapy: Because the kidneys can no longer convert vitamin D into its active form, synthetic versions are used to restore levels. Active vitamin D suppresses parathyroid hormone through several pathways: it increases calcium absorption, makes bones more responsive to parathyroid hormone (so less hormone is needed), and directly reduces parathyroid hormone production at the gene level.
- Calcimimetics: These medications make the parathyroid glands more sensitive to calcium, essentially tricking them into “seeing” higher calcium levels than are actually present. This lowers parathyroid hormone secretion and has also been shown to reduce FGF23, phosphorus, and the calcium-phosphorus product.
Treatment Targets
The most widely followed guidelines, from the international KDIGO group, take a deliberately flexible approach to targets. For phosphorus, the recommendation is to lower elevated levels toward the normal range rather than hitting a specific number. For calcium, the primary goal is avoiding levels that are too high, since excess calcium can accelerate vascular calcification. For parathyroid hormone, the target depends on CKD stage. In patients not yet on dialysis, the focus is on identifying and correcting the causes of rising parathyroid hormone (high phosphorus, low calcium, low vitamin D) rather than targeting a specific level. For patients on dialysis, the suggested range is approximately 2 to 9 times the upper limit of normal for the lab’s assay.
These wide targets reflect the reality that both over-treatment and under-treatment carry risks. Suppressing parathyroid hormone too aggressively can cause adynamic bone disease, while leaving it unchecked drives high-turnover bone loss and vascular calcification. The goal is to keep the system in a manageable range while avoiding the extremes.